Richard Wenzel, PhD
Director, Global Pricing & Access Consulting
Expertise:
As a Director of Global Market Access and Pricing, Richard leads global consulting engagements within EVERSANA.
Richard comes with 13+ year of Life Sciences Consulting and Industry experience. He supported 40+ pharma brands preparing and executing a successful launch – from big pharma to BioTech. Richard’s primary expertise is access & pricing across therapeutic areas and geographies with a focus on oncology and rare diseases. He also has significant experience in fact-based, holistic approaches to (early) portfolio and product strategy, global launch excellence and value demonstration. He is experienced in delivering both, strategic plan and hands-on implementation.
His relevant project experiences include: global launch pricing of breakthrough oncologics in US and ex-US, global go-to-market, global pricing & commercial strategy, LCM strategy, tactical pricing & analytics, competitive simulations, financial forecasting, Search&Evaluation and M&A, brand strategy, value based contracting, patient flow strategy and tactics, and sales force analytics and excellence.
Prior to joining EVERSANA, Richard was a senior principal at IQVIA advising German pharma accounts on launch. He held a Global Value Access & Pricing role at the German BioTech MorphoSys during its expansion phase and managed consulting projects as a Principal for CRA, a boutique consulting firm focused on life science strategy. Prior to that, he was a consultant at SKP. Richard received his PhD and Diploma in physics from ETH Zurich.
Articles by Richard Wenzel, PhD
Winning in the EU JCA Era: Why Proactive Intelligence Will Define Market Access Success
The EU JCA Is Changing the Rules of Market Access The EU Joint Clinical Assessment (JCA) is not simply another regulatory milestone; it represents a fundamental transformation in how clinical evidence will be evaluated, aligned, and translated into market access decisions across Europe. For market access and HEOR teams, this shift creates both opportunity and […]
Predicting PICOs for EU HTA: The Validated PICO Planner Approach Based on Retrospective Analysis
The EU Health Technology Assessment Regulation (EU HTAR) and Joint Clinical Assessment (JCA) aim to harmonize clinical evaluations across Europe while preserving national HTA decisions. To navigate this complexity, early and strategic PICO (Population, Intervention, Comparator, Outcome) planning is essential for effective evidence generation strategies. This study, presented at ISPOR Europe 2025, demonstrates how NAVLIN […]
Strategic PICO Planning: Navigating Oncology Markets with NAVLIN by EVERSANA
Strategic PICO Planning in Oncology Markets In today’s dynamic healthcare environment, early and strategic PICO (Population, Intervention, Comparator, Outcome) planning is critical to successful evidence generation. With evolving regulatory frameworks—like the European Joint Clinical Assessment (JCA)—now leveraging PICOs to guide therapy evaluations, NAVLIN by EVERSANA® enables clients to anticipate HTA requirements, align internal stakeholders, and […]
Strategic PICO Planning: Enhancing Early-Phase Development for Market Access
Future-Proofing Early Development with Strategic PICO Planning A global pharmaceutical company with a diverse pipeline needed to align early clinical planning with future market access requirements—before Phase II. With Target Product Profiles (TPPs) still in development, the team turned to NAVLIN by EVERSANA® to anticipate EU Joint Clinical Assessment (JCA) expectations and build a strategic […]